Gilead Sciences | GILD - Nettoeinkommen

Aktienkurs
130.33
Täglich Wechseln
-3.31 -2.48%
Monatlich
-5.74%
Jährlich
26.33%
Q2 Prognose
134.61




Nettoeinkommen Veränderung Datum
AbbVie USD 1.82B 1.63B 2025-12
Agios Pharmaceuticals USD -108.04M 4.61M 2025-12
ALKERMES USD 49.34M 33.42M 2025-12
Alnylam Pharmaceuticals USD 186.42M 64.66M 2025-12
Amgen USD 1.33B 1.88B 2025-12
Biogen USD 466.5M 168.3M 2025-09
BioMarin Pharmaceutical USD -46.57M 15.83M 2025-12
Bristol-Myers Squibb USD 1.09B 1.11B 2025-12
Coherus Biosciences USD -37.64M 2.11M 2025-12
Eli Lilly USD 6.64B 1.05B 2025-12
Gilead Sciences USD 2.18B 869M 2025-12
GlaxoSmithKline GBP 636M 1.38B 2025-12
Glaxosmithkline GBP 846.06M 1.87B 2025-12
Incyte USD 299.28M 124.89M 2025-12
J&J USD 5.24B 119M 2026-03
Merck USD 2.96B 2.82B 2025-12
Moderna USD -200M 625M 2025-09
Neurocrine Biosciences USD 209.5M 102M 2025-09
Novartis USD 2.41B 1.52B 2025-12
Pfizer USD -1.65B 5.19B 2025-12
PTC Therapeutics USD -134.96M 150.86M 2025-12
Puma Biotechnology USD 20.32M 24.85M 2024-09
Regeneron Pharmaceuticals USD 844.6M 615.4M 2025-12
Sangamo BioSciences USD -36.13M 12.96M 2024-06
Sanofi EUR 1.61B 2.42B 2026-03
Sarepta Therapeutics USD -412.23M 232.28M 2025-12
United Therapeutics USD 364.3M 25.6M 2025-12
Vertex Pharmaceuticals USD 1.19B 108.2M 2025-12